Business Wire

SKILLCELL

1.10.2020 18:25:11 CEST | Business Wire | Press release

Share
EasyCOV, the Virological Saliva Test for COVID19 Confirms Its Excellent Results: a Sensitivity of 88% and a Specificity of 99% in 40 Min

EasyCOV, a virological saliva detection test for COVID19, has shown a sensitivity of 88% and a specificity 99% during a clinical trial performed at the testing center operated by the teaching hospital of Montpellier. The test relies on an optimized thermal protocol that provides the results in 40 minutes.

EasyCOV, developed by SkillCell in collaboration with the CNRS (French National Center for Scientific Research), is a saliva test that can be run in the field and that provides results in the form of a change of color in no more than 40 minutes. Performed by a healthcare professional, the test requires the collection of 200 microliters of saliva, approximately 4 drops, from under the patient’s tongue. The sample is heated successively in two tubes using the nomadic heating device EasyVID (developed and produced by TRONICO, sister company of SkillCell). A test turning bright yellow indicates that the virus has been detected while an orange test is negative.

A double-blind clinical trial has been conducted at the teaching hospital of Montpellier, France, in real life conditions at the testing center operated by the hospital. During this clinical trial, nasopharyngeal and saliva samples were collected simultaneously and analyzed via RT PCR. These two analyses were used as a basis to establish the infection status of the participants. This status was then compared to the results of EasyCOV test. This analysis showed a sensitivity of 87.5% and a specificity of 99.4% for 220 participants, including 40 positive patients with and without symptoms. EasyCOV test was performed using a thermal protocol giving results in 40 min.

EasyCOV demonstrates with this trial that it is high quality, faster, cost-efficient and not invasive test that can be performed in a large variety of locations without requiring heavy investments.

Alexandra Prieux, President of SkillCell commented « EasyCOV is a unique and necessary tool in the fight against COVID 19. It is a real satisfaction for the team that our test is able to bring a concrete answer to the sanitary and economic challenges that we face today. ».

The EasyCov programme is supported by the French Ministry of Armed Forces via the Direction Générale de l’Armement (Directorate General of Armaments - DGA) and the Agence de l’Innovation de Défense (Defense Innovation Agency - AID).

About SKILLCELL

SkillCell develops in-field diagnostic tests using its simplicity-centered approach: tests capable of being used by anybody, anywhere and at any time. Founded in Guadeloupe in 2017, the company has offices in France in Jarry (Guadeloupe), Paris and Montpellier. The SkillCell team brings together scientific experts and seasoned manufacturers to find solutions to medical and environmental diagnostic testing issues by providing relevant, high-quality information that allows users to make well-informed choices with full transparency. SkillCell is a subsidiary of ALCEN group. For more information: www.skillcell-alcen.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

MANE Selects Kinaxis to Strengthen Global Planning Capabilities29.6.2026 13:00:00 CEST | Press release

Kinaxis Maestro™ platform to provide the digital foundation to strengthen MANE’s global planning capabilities and support its continued planning transformation Kinaxis®(TSX:KXS), a global leader in end-to-end supply chain planning and orchestration, today announced that MANE, one of the top five leading organizations worldwide in the flavours and fragrances industry, has selected Kinaxis to modernize its planning capabilities as it accelerates global growth as part of a broader enterprise-wide transformation initiative. Headquartered in the south of France, with a significant global footprint spanning multiple regions and customers across international markets, MANE is known for its innovation, technical expertise and strong commitment to sustainability. The company is investing in more connected, end-to-end planning capabilities to support continued growth and increasing operational complexity worldwide. Following an extensive evaluation process with major competitors in the market, M

From Abu Dhabi to Imola: A2RL Expands Internationally with Historic Autonomous Racing Debut at Iconic Italian Track29.6.2026 12:12:00 CEST | Press release

A2RL’s first international race marks a major step towards its ambition to become the world’s first international championship for fully autonomous racecarsUp to 5 teams including TUM, PoliMOVE, Unimore, Kinetiz and Constructorselected from the 2025 season will compete in the world’s first autonomous multi-car race in EuropeA2RL engaged Italy’s motorsport, engineering and student communities through Motor Valley Fest and a university roadshow ahead of the raceFollowing European debut at Imola, the 2026 season will conclude at Yas Marina Circuit in Abu Dhabi The Abu Dhabi Autonomous Racing League, A2RL, will make its international racing debut on 5 September 2026 in Imola, Italy, bringing up to 5 fully autonomous racecars based on the Dallara Super Formula SF23 to one of the world’s most iconic and demanding racing circuits. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629726789/en/ From Abu Dhabi to Imola: A2RL Expands

Philip Morris International and Maestro Andrea Bocelli Present “Believe. Further”29.6.2026 12:00:00 CEST | Press release

A new platform for dialogue on progress, reflecting a mutual commitment to advancing positive change Philip Morris International (PMI) (NYSE: PM) and Maestro Andrea Bocelli today presented “Believe. Further”, a multi-year platform designed to engage audiences in a broader conversation on progress and positive change. The launch took place at the Torre dell’Arsenale in Venice, where heritage and forward movement meet, a fitting setting for two voices on a similar path. What do you do when the world has already decided what you are? “Believe. Further” begins from that question. It is built around a shared belief in progress and a shared conviction in transformation. At a time when science and technology allow better choices, it brings together two voices that, independently and in parallel, are undergoing a change in motion, and invites the beginning of a different conversation with society at large. Maestro Bocelli’s journey has been defined by belief. From the beginnings of his career

Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release

Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie

Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release

Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye